Opinion
Video
The expert panelists provide their final insights surrounding the future of HCC treatment management.
Zanidatamab Demonstrates Activity in Pretreated HER2+ Biliary Tract Cancer
Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting
EMA Validates Application for Nivolumab Plus Ipilimumab in Frontline HCC
D'Amato Discusses Research and Resistance Mechanisms in Sarcoma and Gastrointestinal Stromal Tumor
RMC-6236 Shows Activity With Favorable Toxicity Profile in Previously Treated PDAC
Innovative Research Continues to Propel Individualized GIST Treatments
Dr Backhus on Surgical Eligibility in Borderline Resectable NSCLC
Dr Herbst on the Importance of Multidisciplinary Collaboration in NSCLC
Enhanced Clinical Education and Simplified Guidelines Needed to Address Germline Testing Gaps in Breast Cancer
Research Propels Additional Options into the Advanced HER2+ Breast Cancer Armamentarium